BioSpace News Archive

Lazarus 3D received its first 510(k) clearance from the Food and Drug Administration (FDA) for its patented PRE-SURE® technology. Lazarus 3D’s PRE-SURE® models are created in synthetic, soft-tissue materials that can be cut, sutured, and can even bleed.

At the Alzheimer’s Association International Conference® (AAIC®) 2021, in Denver and virtually, researchers shared new evidence-based insights into why people from communities of color do and do not choose to participate in clinical trials.

Today at the Alzheimer’s Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaque changes following donanemab treatment was highly associated with less cognitive decline and participants with greater plaque clearance at 24 weeks of treatment showed less tau progression

Better Therapeutics, Inc. (“Better Therapeutics”), in partnership with Colorado Prevention Center (CPC) Clinical Research, affiliated with the University of Colorado Anschutz Medical Campus, today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes.

CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced that the management team will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s second quarter 2021 financial results on Thursday, August 5, 2021 after the close of U.S. financial markets.

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that it will release its financial results for the second quarter ended June 30, 2021, before the open of the financial markets on Thursday, August 5, 2021.

Travere Therapeutics, Inc. reported its second quarter 2021 financial results and provided a corporate update.

OPKO Health, Inc. reports business highlights and financial results for the three months ended June 30, 2021.

Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform oncology drug discovery and development today announced financial results for the second quarter ended June 30, 2021.